Funding Received
$129.6 Million in 7 Rounds from 4 Investors
Most Recent Funding
$12 Million Series B on July 28, 2014
Founded:
2007
Headquarters:
Menlo Park, CA
Description:
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases, including influenza.
Categories:
Biotechnology
Website:
http://paxvax.com

Detailed Description

Update

PaxVax is a vaccine start-up company developing candidate oral vaccines for influenza, and key infectious diseases.

PaxVax has developed a proprietary oral vaccine technology based on a common virus called adenovirus. The technology removes the delivery hurdles of traditional injectable vaccines, namely the need for cold storage, needles, and administration by medical personnel.

PaxVax has raised more than $50 million from investors including Ignition Partners and the Wellcome Trust, and is supported by grants from the U.S. National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID) and its Division of Acquired Immunodeficiency Syndrome (DAIDS), as well as the Bill and Melinda Gates Foundation.

Current Team (8)

Update

Funding Rounds (7) - $129.6M

Update

Board Members and Advisors (5)

Update

Investors (4)

Update

Offices/Locations (2)

Update
  • San Diego Office

    3985A Sorrento Valley Boulevard

    San Diego, CA 92121

    USA

  • Menlo Park Office

    1010 El Camino Real, STe 380

    Menlo Park, CA 94025

    USA